Choice of early and escalation treatment options for multiple sclerosis;Therapieentscheidungen bei multipler sklerose: Aktuelles zur früh- und eskalationstherapie

Nervenarzt

Volumn 79, Issue 10, 2008, Pages 1123-1134

  Linker, R A ^a   Kieseier, B C ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Clinically isolated syndrome; Early treatment; Escalation therapy; Immunomodulation; Mitoxantrone; Multiple sclerosis; Natalizumab; Rituximab

Indexed keywords

ALIZAPRIDE; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB;

CLINICAL TRIAL; CONSENSUS; DEMYELINATION; DISEASE SEVERITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; RECURRENT DISEASE; REMISSION; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 53949108741     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-008-2521-3     Document Type: Review

References (59)

1. Rodriguez 1995 Neurology 45 244
2. Tintore 2006 Neurology 67 968
3. Tintore 2008 Neurology 70 1079
4. McDonald 2001 Ann Neurol 50 121
5. Polman 2005 Ann Neurol 58 840
6. Frohman 2003 Neurology 61 602
7. Wujek 2002 J Neuropathol Exp Neurol 61 23
8. Kuhlmann 2002 Brain 125 2202
9. Hirst CL, Swingler R, Compston A et al. (2008) Survival and cause of death in multiple sclerosis: a prospective population based study. J Neurol Neurosurg Psychiatry (in press)
10. Kremenchutzky 2006 Brain 129 584
11. Confavreux 2000 N Engl J Med 343 1430
12. Dalton 2002 Ann Neurol 52 47
13. Fisniku 2008 Brain 131 808
14. Filippi 1994 Neurology 44 635
15. Jacobs 2000 N Engl J Med 343 898
16. Comi 2001 Lancet 357 1576
17. Beck 2002 Ann Neurol 51 448
18. Kinkel 2006 Neurology 66 678
19. Kappos 2006 Neurology 67 1242
20. Polman 2008 J Neurol 255 480
21. Kappos 2007 Lancet 370 389
22. Hartung 2007 J Neurol 254 827
23. Rieckmann 2006 Nervenarzt 77 1506
24. Ransohoff 2007 N Engl J Med 356 2622
25. Baron 1993 J Exp Med 177 57
26. Andrian 2003 N Engl J Med 348 68
27. Miller 2003 N Engl J Med 348 15
28. Polman 2006 N Engl J Med 354 899
29. Rudick 2007 Ann Neurol 62 335
30. Kleinschmidt-DeMasters 2005 N Engl J Med 353 369
31. Langer-Gould 2005 N Engl J Med 353 375
32. Van 2005 N Engl J Med 353 362
33. Yousry 2006 N Engl J Med 354 924
34. Stuve 2006 Arch Neurol 63 1383
35. Zohren 2008 Blood 111 3893
36. Gold 2007 J Neuroimmunol 187 156
37. Kappos 2007 Lancet Neurol 6 431
38. Mullen 2008 N Engl J Med 358 647
39. Yao 2008 PLoS ONE 3 e2028
40. Phillips 2006 Neurology 67 1717
41. Hellwig 2008 Arch Neurol 65 656
42. Krumbholz 2007 Arch Neurol 64 1331
43. Leussink 2008 Arch Neurol 65 851
44. Haghikia 2008 Nervenarzt 79 716
45. Neuhaus 2004 Expert Rev Neurother 4 17
46. Chan 2005 Clin Exp Immunol 139 152
47. Hartung 2002 Lancet 360 2018
48. Strotmann 2002 Am J Cardiol 89 1222
49. Cotte S, Kruse N, Ahsen N von et al. (2008) ABC-Tranporter gene polymorphisms: potential predictors of therapeutic efficacy of mitoxantrone in mutiple sclerosis. Neurology [Suppl 11] 70: A395
50. Vollmer 2008 Mult Scler 14 663
51. Edan 1997 J Neurol Neurosurg Psychiatry 62 112
52. Gladstone 2006 Arch Neurol 63 1388
53. La 2007 Cochrane Database Syst Rev 1 CD002819
54. Linker 2008 Exp Neurol 211 397
55. Cross 2006 J Neuroimmunol 180 63
56. Petereit 2005 Arch Neurol 62 1641
57. Stuve 2005 Arch Neurol 62 1620
58. Bar-Or 2008 Ann Neurol 63 395
59. Hauser 2008 N Engl J Med 358 676